Sera Prognostics Revenue and Competitors
Estimated Revenue & Valuation
- Sera Prognostics's estimated annual revenue is currently $20.3M per year.
- Sera Prognostics's estimated revenue per employee is $263,701
- Sera Prognostics's total funding is $250.3M.
Employee Data
- Sera Prognostics has 77 Employees.
- Sera Prognostics grew their employee count by -9% last year.
Sera Prognostics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.8M | 5 | -17% | N/A | N/A |
#2 | $1.4M | 9 | -10% | N/A | N/A |
#3 | $5.9M | 38 | 41% | N/A | N/A |
#4 | $1.1M | 7 | -53% | N/A | N/A |
#5 | $1.6M | 10 | 11% | N/A | N/A |
#6 | $21.2M | 137 | 10% | N/A | N/A |
#7 | $1.6M | 33 | -48% | $17.8M | N/A |
#8 | $1.9M | 12 | 0% | N/A | N/A |
#9 | $3.7M | 24 | 9% | N/A | N/A |
#10 | $0.9M | 6 | 0% | N/A | N/A |
What Is Sera Prognostics?
In collaboration with the National Institutes of Health Maternal Fetal Medicine Network, Sera's scientific cofounders, Steven W. Graves, Ph.D., a professor in the department of Chemistry and Biochemistry at Brigham Young University and M. Sean Esplin, M.D., an associate professor and high-risk obstetrician at the University of Utah School of Medicine, identified biomarkers detectable from simple blood tests that can help predict the likelihood of preterm delivery and other pregnancy complications. Sera Prognostics has exclusively licensed rights to the preterm birth and preeclampsia biomarkers and the proteomics discovery technology for use in developing diagnostics to help predict and manage pregnancy complications.
keywords:N/A
$250.3M
Total Funding
77
Number of Employees
$20.3M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Sera Prognostics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Scientific Officer | Reveal Email/Phone |
2 | Chief Information Officer (CIO) | Reveal Email/Phone |
3 | Scientist II | Reveal Email/Phone |
4 | Data Science Consultant | Reveal Email/Phone |
5 | Director Project Management | Reveal Email/Phone |
6 | VP, Commercial Operations, Analytics, and Billing | Reveal Email/Phone |
7 | General Counsel | Reveal Email/Phone |
8 | Senior Revenue Cycle Manager | Reveal Email/Phone |
9 | Director Experience Strategy | Reveal Email/Phone |
10 | VP Commercialization | Reveal Email/Phone |
Sera Prognostics News
JANE F. BARLOW TO THE SERA PROGNOSTICS BOARD. Published: Apr 12, 2022. - Accomplished business and health services leader joins Sera in its quest to improve...
Good afternoon and welcome to the Sera Prognostics' conference call to review fourth quarter and fiscal year of 2021 results.
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care.
Brings extensive data science, bioinformatics and proteomics experience to foster further product innovation and informed healthcare insights into pregnancy SALT LAKE CITY, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ: SERA), focused on improving mate ...
SALT LAKE CITY, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that according to a preliminary list ...
Other Companies in Millcreek
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $20.8M | 99 | 10% | N/A |
#2 | $54M | 152 | 3% | N/A |
#3 | $40.9M | 248 | 6% | N/A |
#4 | $102.8M | 344 | -1% | N/A |
#5 | $175.9M | 620 | 10% | N/A |